What explains the intraday drop in 42C.SI stock today?

The intraday drop in 42C.SI stock reflects profit-taking after recent gains, mixed healthcare sector flows, and investor caution over valuation and near-term clinical catalysts.

What is Meyka AI's price forecast for 42C.SI stock?

Meyka AI's forecast model projects a quarterly price of S$0.27 for 42C.SI stock, which implies an estimated upside of 22.73% versus the current S$0.22. Forecasts are projections, not guarantees.

How does valuation look for 42C.SI stock?

Valuation for 42C.SI stock is stretched: PE **-20.50** (loss-making), PB **43.71**, and P/S **25.32**, highlighting premium pricing relative to earnings and book value.

Should I trade 42C.SI stock intraday or hold longer term?

For intraday traders, volume and volatility can offer short-term moves; for longer-term investors, wait for clearer clinical or commercial milestones given negative EPS and mixed ratings on 42C.SI stock.

SG Stocks

Top intraday loser: iX Biopharma (42C.SI) at S$0.22 on 26 Feb 2026: catalyst watch

ByDanny Kontos February 26, 2026February 26, 2026

The 42C.SI stock is trading at S$0.22 intraday on 26 Feb 2026, marking it among the top losers on the Singapore Exchange (SES) this session. We see elevated activity with a volume of 9,444,400 shares versus a 50-day average of 13,972,362, and a 1-day move of -6.82%. Investors are weighing mixed clinical updates, tight cash metrics and volatile sector flows in Healthcare. As active traders react, we track valuation, technical signals and Meyka AI forecasts to frame the immediate outlook.